StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $6.95 | $6.82 | -1.82% | 0.0M |
| 05-18 | $6.95 | $6.83 | -1.73% | 0.0M |
| 05-19 | $6.78 | $6.80 | +0.29% | 0.0M |
| 05-20 | $6.85 | $6.95 | +1.46% | 0.0M |
| 05-21 | $6.93 | $6.94 | +0.14% | 0.0M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for KYNB yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $3.74M | $6.44M | $5.16M | $4.09M |
Operating Income | $-13.82M | $-45.90M | $-32.38M | $-26.97M |
Net Income | $-15.20M | $183.45M | $197.67M | $-2.96M |
EPS (Diluted) | $-3.76 | $45.37 | $48.90 | $-0.73 |
Total Assets | $109.63M | $119.59M | $137.01M | $178.06M |
Total Liabilities | $118.92M | $115.12M | $119.53M | $359.08M |
Cash & Equivalents | $37.00M | $47.87M | $117.97M | $23.37M |
Free Cash Flow OCF − CapEx | $-13.89M | $-4.81M | $13.52M | $15.37M |
Shares Outstanding | 4.05M | 4.05M | 4.04M | 4.04M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.